Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy With oXiris Membrane
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Oct 8, 2022
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called the oXiris membrane, which is used in a procedure known as continuous renal replacement therapy (CRRT) for patients experiencing severe acute kidney injury due to sepsis. Sepsis is a serious condition that occurs when the body has a severe response to infection, leading to organ damage. The trial aims to find out if the oXiris membrane can help improve the stability of blood circulation in these patients compared to standard treatments.
To participate in this trial, individuals need to be at least 18 years old and have acute kidney injury related to sepsis that requires CRRT. Unfortunately, those who cannot have their blood pressure and heart activity monitored will not be eligible. Participants in the trial will have the opportunity to receive this new treatment while being closely monitored to understand its effects. The trial is currently recruiting, and it welcomes individuals of all genders who meet the eligibility criteria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged ≥ 18 years
- • Sepsis related acute kidney injury requiring continuous renal replacement therapy
- Exclusion Criteria:
- • • No monitoring of blood pressure and ECG
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Seung Seok Han, M.D.
Principal Investigator
Seoul National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials